147 related articles for article (PubMed ID: 1580300)
1. Prognostic indicators in node-negative early stage breast cancer.
Wong WW; Vijayakumar S; Weichselbaum RR
Am J Med; 1992 May; 92(5):539-48. PubMed ID: 1580300
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
6. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
7. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients.
Fisher ER; Redmond C; Fisher B; Bass G
Cancer; 1990 May; 65(9 Suppl):2121-8. PubMed ID: 2328478
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significances of estrogen and progesterone receptors in primary operable breast cancer.
Kurebayashi J; Ishida T; Higashi Y; Suemasu K; Nomoto C; Yoshida K
Jpn J Clin Oncol; 1990 Sep; 20(3):271-80. PubMed ID: 2255103
[TBL] [Abstract][Full Text] [Related]
9. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group.
Seshadri R; Horsfall DJ; Firgaira F; McCaul K; Setlur V; Chalmers AH; Yeo R; Ingram D; Dawkins H; Hahnel R
Int J Cancer; 1994 Jan; 56(1):61-5. PubMed ID: 8262679
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors. Stage and receptor status in breast cancer.
Donegan WL
Cancer; 1992 Sep; 70(6 Suppl):1755-64. PubMed ID: 1516031
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
Allred DC; Clark GM; Tandon AK; Molina R; Tormey DC; Osborne CK; Gilchrist KW; Mansour EG; Abeloff M; Eudey L
J Clin Oncol; 1992 Apr; 10(4):599-605. PubMed ID: 1548522
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
14. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
Masood S
Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
[TBL] [Abstract][Full Text] [Related]
15. Indicators of prognosis in node-negative breast cancer.
Sigurdsson H; Baldetorp B; Borg A; Dalberg M; Fernö M; Killander D; Olsson H
N Engl J Med; 1990 Apr; 322(15):1045-53. PubMed ID: 2320064
[TBL] [Abstract][Full Text] [Related]
16. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive factors in early-stage breast cancer.
Cianfrocca M; Goldstein LJ
Oncologist; 2004; 9(6):606-16. PubMed ID: 15561805
[TBL] [Abstract][Full Text] [Related]
18. Nuclear characteristics as indicators of prognosis in node negative breast cancer patients.
le Doussal V; Tubiana-Hulin M; Hacene K; Friedman S; Brunet M
Breast Cancer Res Treat; 1989 Nov; 14(2):207-16. PubMed ID: 2605347
[TBL] [Abstract][Full Text] [Related]
19. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
20. Prognostic indicators in invasive breast cancer.
Sunderland MC; McGuire WL
Surg Clin North Am; 1990 Oct; 70(5):989-1004. PubMed ID: 2218829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
